CEO – Talk Bio

Hikma announces CEO change and Board appointment

2 weeks ago talkbio0Tagged * * Riad Mishlawi * *, Board appointment, CEO, Changing, Darwazah, executive leadership, Hikma Pharmaceuticals, Khalid Nabilsi, London

Hikma Pharmaceuticals; CEO change; Riad Mishlawi; Said Darwazah; Khalid Nabilsi; Board appointment; executive leadership; pharmaceuticals; London; 15 December 2025

Enliven Therapeutics Announces New CEO

3 weeks ago talkbio0Tagged CEO, ELVN, Enliven Therapeutics, Leadership, Myeloid Leukemia, Chronic, Phase 3 trial, Richard Fair, Rick Fair, Transition Mutation

Enliven Therapeutics; ELVN; new CEO; Rick Fair; Richard Fair; Sam Kintz; leadership transition; Phase 3 trial; ELVN-001; chronic myeloid leukemia; CML; biotech; Nasdaq ELVN

Zentek Appoints Mohammed Jiwan as CEO

1 month ago talkbio0Tagged Appointments, CEO, commercialization, Graphene, Jiwan, Mohammed, Nanostructured Materials, Technology, ZenGUARD, Zentek

Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization

ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy

1 month ago talkbio0Tagged Appointments, Biotechnology, CEO, Immunotherapy for cancer, Keren Leshem, Leadership, RNA-LNP, ViVac Pharma

ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology

Major Leadership Changes and Fundraising in Biotech: Metagenomi CEO Exit, Workforce Cuts; Cogent Biosciences Raises Over $475M

2 months ago talkbio0Tagged bezuclastinib, Brian Thomas, CEO, Cogent Biosciences, Exit, Fund Raising, hemophilia A program, Irish (ethnic group), Jian, layoffs, Metagenomi, pipeline focus, Workforce

Metagenomi; CEO exit; Brian Thomas; Jian Irish; workforce cuts; biotech layoffs; Cogent Biosciences; fundraising; bezuclastinib; hemophilia A program; pipeline focus

Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders

2 months ago talkbio0Tagged Accuray, cell transformation, CEO, Change, Organizational, executive appointments, Leadership, med-tech, operational transformation, Steve La Neve, Suzanne Winter, Transition Mutation

Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition

The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures

3 months ago talkbio0Tagged Belén, Biopharma, CEO, Garijo, Leadership, Reshma Kewalramani, Sarah Boyce, Woman, Women, Yvonne Greenstreet

powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership

GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026

3 months ago talkbio0Tagged Appointments, CEO, Emma Walmsley, Leadership Transition, Luke Miels, R&D pipeline, SmithKline Beecham, specialty medicines, Vaccines

GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond

3 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Breakthrough Therapy, Cancer of Neck, CEO, expansion, Genmab, Head, Merus, Neoplasms, Perspective, Petosemtamab, pipeline, United States Food and Drug Administration

Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

3 months ago talkbio0Tagged CEO, Drug Industry, Emma Walmsley, Haleon demerger, Leadership Change, Luke Miels, SmithKline Beecham, specialty medicines, Succession planning, Transition Mutation, Vaccines

Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning